Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide.
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.
Octreotide is second peptide molecule in Shilpa' s peptide portfolio. The CEP showcases our expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 879.90 as compared to the previous close of Rs. 863.40. The total number of shares traded during the day was 42509 in over 2373 trades.
The stock hit an intraday high of Rs. 917.20 and intraday low of 874.05. The net turnover during the day was Rs. 38019239.00. |
